Cargando…

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations

Breast cancer was one of the first malignancies to benefit from targeted therapy, i.e., treatments directed against specific markers. Inhibitors against HER2 are a significant example and they improved the life expectancy of a large cohort of patients. Research on new biomarkers, therefore, is alway...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falcone, Italia, Conciatori, Fabiana, Bazzichetto, Chiara, Bria, Emilio, Carbognin, Luisa, Malaguti, Paola, Ferretti, Gianluigi, Cognetti, Francesco, Milella, Michele, Ciuffreda, Ludovica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696061/ https://www.ncbi.nlm.nih.gov/pubmed/33182542 http://dx.doi.org/10.3390/ijms21228419

Ejemplares similares

Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement
por: Conciatori, Fabiana, et al.
Publicado: (2019)

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
por: Falcone, Italia, et al.
Publicado: (2020)

mTOR Cross-Talk in Cancer and Potential for Combination Therapy
por: Conciatori, Fabiana, et al.
Publicado: (2018)

Role of mTOR Signaling in Tumor Microenvironment: An Overview
por: Conciatori, Fabiana, et al.
Publicado: (2018)

Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer
por: Bazzichetto, Chiara, et al.
Publicado: (2019)

PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy
por: Conciatori, Fabiana, et al.
Publicado: (2020)

PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
por: Bazzichetto, Chiara, et al.
Publicado: (2019)

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition
por: Conciatori, Fabiana, et al.
Publicado: (2022)

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
por: Bazzichetto, Chiara, et al.
Publicado: (2020)

BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer
por: Conciatori, Fabiana, et al.
Publicado: (2020)

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology
por: Bazzichetto, Chiara, et al.
Publicado: (2020)

PTEN: Multiple Functions in Human Malignant Tumors
por: Milella, Michele, et al.
Publicado: (2015)

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
por: Valenti, Fabio, et al.
Publicado: (2021)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Editorial: Tailoring immunotherapy in gastrointestinal cancer: the role of circulating factors
por: Ugel, Stefano, et al.
Publicado: (2023)

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
por: Gkountakos, Anastasios, et al.
Publicado: (2019)

Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic Biomarker
por: Bazzichetto, Chiara, et al.
Publicado: (2022)

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
por: Milella, Michele, et al.
Publicado: (2017)

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response
por: Martelli, Alberto M., et al.
Publicado: (2019)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2011)

Targeting targeted agents: open issues for clinical trial design
por: Bria, Emilio, et al.
Publicado: (2009)

Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories
por: Sposito, Marco, et al.
Publicado: (2023)

Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence.
por: Garufi, Giovanna, et al.
Publicado: (2020)

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
por: Garufi, Giovanna, et al.
Publicado: (2021)

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
por: Carbognin, Luisa, et al.
Publicado: (2015)

Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome
por: Trestini, Ilaria, et al.
Publicado: (2020)

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021)

AXL is an oncotarget in human colorectal cancer
por: Martinelli, Erika, et al.
Publicado: (2015)

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2010)

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
por: Fabi, Alessandra, et al.
Publicado: (2016)

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
por: Fabi, Alessandra, et al.
Publicado: (2015)

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
por: Rossi, Valentina, et al.
Publicado: (2019)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

The protective side of progesterone
por: Ferretti, Gianluigi, et al.
Publicado: (2007)

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
por: Loria, Rossella, et al.
Publicado: (2022)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study
por: Trestini, Ilaria, et al.
Publicado: (2021)

The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels
por: Fritz, Helena K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_30g8qvnomtluardv7c527drv8k